Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Among authors: kodani m. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
Loss of imprinting of PEG1/MEST in lung cancer cell lines.
Nakanishi H, Suda T, Katoh M, Watanabe A, Igishi T, Kodani M, Matsumoto S, Nakamoto M, Shigeoka Y, Okabe T, Oshimura M, Shimizu E. Nakanishi H, et al. Among authors: kodani m. Oncol Rep. 2004 Dec;12(6):1273-8. Oncol Rep. 2004. PMID: 15547750
UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study.
Igishi T, Shigeoka Y, Yasuda K, Suyama H, Katayama S, Sugitani A, Matsumoto S, Yamamoto M, Ueda Y, Takeda K, Sumikawa T, Sako T, Kodani M, Hitsuda Y, Shimizu E. Igishi T, et al. Among authors: kodani m. J Thorac Oncol. 2009 Mar;4(3):376-82. doi: 10.1097/JTO.0b013e3181989dfc. J Thorac Oncol. 2009. PMID: 19190514 Free article. Clinical Trial.
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
Ueda Y, Igishi T, Hashimoto K, Suyama H, Araki K, Sumikawa T, Takeda K, Nakazaki H, Matsunami K, Kodani M, Shigeoka Y, Matsumoto S, Shimizu E. Ueda Y, et al. Among authors: kodani m. Int J Oncol. 2009 Mar;34(3):689-96. doi: 10.3892/ijo_00000195. Int J Oncol. 2009. PMID: 19212674
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Ito S, Igishi T, Takata M, Ueda Y, Matsumoto S, Kodani M, Takeda K, Izumi H, Sakamoto T, Yamaguchi K, Makino H, Touge H, Chikumi H, Shimizu E. Ito S, et al. Among authors: kodani m. Int J Oncol. 2014 Mar;44(3):685-92. doi: 10.3892/ijo.2014.2249. Epub 2014 Jan 8. Int J Oncol. 2014. PMID: 24399305
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Izumi H, Touge H, Igishi T, Makino H, Nishii-Ito S, Takata M, Nakazaki H, Ueda Y, Matsumoto S, Kodani M, Kurai J, Takeda K, Sakamoto T, Yanai M, Tanaka N, Nirodi CS, Shimizu E. Izumi H, et al. Among authors: kodani m. Int J Oncol. 2015 Mar;46(3):989-98. doi: 10.3892/ijo.2015.2815. Epub 2015 Jan 7. Int J Oncol. 2015. PMID: 25573239 Free PMC article. Clinical Trial.
104 results